RSV is a virus that can make people sick, especially older adults and babies. But even though RSV can be serious, people aren't as worried about it anymore. RSV is common but can be dangerous ...

New phase 2b/3 trial results with MSD's experimental respiratory syncytial virus (RSV) antibody clesrovimab have fired a shot across the bows of AstraZeneca and Sanofi, currently predicting ...

Respiratory syncytial virus (RSV) remains the top cause of hospitalization among young children, leading to respiratory issues like bronchiolitis and pneumonia. However, the reasons why some ...

Oct. 18, 2024 – Older people who aren’t sure about whether to get the vaccine for respiratory syncytial virus (RSV) now have a new set of data to help them make up their minds. A large study ...

Recommended Reading Sanofi readies to meet US demand for RSV antibody An experimental antibody drug developed by Merck & Co. significantly reduced the incidence of disease due to respiratory ...

In years prior to the availability of an RSV vaccine, an estimated 60,000 to 160,000 RSV-associated hospitalizations and 6,000 to 10,000 RSV-associated deaths occurred annually among U.S. adults ...

Real-World Study Confirms RSV Vaccine's Protective Power for Seniors By Ernie Mundell HealthDay Reporter FRIDAY, Oct. 18, 2024 (HealthDay News) -- A global real-world study of the vaccine for ...

Researchers said the RSV vaccines gave approximately 80% protection against severe disease and hospitalization, intensive care unit admission and death in 28,271 people over 60 who were ...

Today, we talk about some RSV competition that’s brewing, how Alnylam’s CEO spoke about its plans with ATTR-CM, and more. Alnylam Pharmaceuticals is expanding the footprint of its RNA-based ...

Cold and flu season — otherwise known as mid-October — is upon us. But this year, several advancements in vaccines could help families keep viruses at bay. One of the new developments is a ...

The incidence of adverse events (AEs) and serious adverse events were comparable between the clesrovimab and placebo groups, and there were no treatment or RSV-related deaths during the study.

A global real-world study of the vaccine for respiratory syncytial virus (RSV) finds it offers folks aged 60 and over 80% protection against severe illness and/or hospitalization. With U.S ...